Isoprinosine enhances the activation of sensitized lymphocytes by Epstein-Barr virus antigens.
Isoprinosine, a synthetic purine derivative and a potentially useful immunostimulating agent, was tested for its ability to enhance lymphocyte responses to Epstein-Barr virus (EBV) antigens and to autologous EBV-transformed lymphocytes. Isoprinosine significantly enhanced the response of sensitized lymphocytes (i.e. from EBV-seropositive individuals) to EBV antigens, while it has no effect on the lack of response of unsensitized lymphocytes (i.e. from EBV-seronegative individuals) to these antigens. In addition, isoprinosine enhanced lymphocytes response to autologous EBV-transformed cells, and potentiated the generation of cytotoxic lymphocytes. From these observations, and since immunosuppression is commonly observed in EBV-associated malignancies and other EBV-induced disorders, it may be important to point out that the use of isoprinosine as an immunostimulating agent in patients with these diseases deserves serious consideration.
S K
SK
Sundar
G
G
Barile
J
J
Menezes
D000956:Antigens, Viral / Q000276:immunology*; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004357:Drug Synergism; D000939:Epitopes; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007288:Inosine / Q000031:analogs & derivatives*; D007542:Inosine Pranobex / Q000494:pharmacology*; D007700:Kinetics; D008213:Lymphocyte Activation / Q000187:drug effects*; D007959:Lymphocyte Culture Test, Mixed; D008214:Lymphocytes / Q000276:immunology*; D010835:Phytohemagglutinins / Q000494:pharmacology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000956:Antigens, Viral; D000939:Epitopes; D010835:Phytohemagglutinins; D007288:Inosine; D007542:Inosine Pranobex